Lenvima

Lenvatinib, the active ingredient in Lenvima, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats certain advanced cancers such as differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma in adult patients.

GNH USA supplies Lenvima as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenvima (lenvatinib) is used in oncology to target tumors that rely on multiple growth‑factor pathways.

Radioiodine‑refractory differentiated thyroid cancer: prolongs progression‑free survival in adult patients. Advanced renal cell carcinoma: improves overall survival when used alone or with pembrolizumab. Unresectable hepatocellular carcinoma: delays tumor growth in patients not eligible for surgery. Advanced endometrial carcinoma: provides disease control after prior systemic therapy.

Lenvima may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure often requiring monitoring or medication. - Diarrhea: watery stools that may lead to dehydration. - Fatigue: persistent tiredness affecting daily activities. - Decreased appetite: reduced desire to eat, potentially causing weight loss.

Serious or Rare Side Effects: - Hepatic failure: signs of liver dysfunction such as jaundice or elevated enzymes. - Cardiac ischemia: chest pain or heart‑attack symptoms. - Gastrointestinal perforation: severe abdominal pain and infection risk. - Severe hemorrhage: uncontrolled bleeding, including nosebleeds or gastrointestinal bleeding.

Before initiating therapy, clinicians should evaluate several safety parameters. - Blood pressure monitoring: check regularly and manage hypertension promptly. - Liver function tests: assess baseline and periodic hepatic enzymes. - Cardiac evaluation: perform ECG and assess for ischemic disease before starting. - Pregnancy risk: avoid use in pregnancy; drug is Category D. - Drug interactions: review concomitant medications for CYP3A4 substrates. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lenvima interacts with several medicines; some combinations should be avoided while others require close observation.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenvatinib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increased risk of bleeding. - High‑dose aspirin or NSAIDs: may exacerbate bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole, erythromycin): may increase plasma levels. - Diuretics: may potentiate hypertension. - Levothyroxine: may require dose adjustment due to altered thyroid hormone metabolism.